Research Report

Mutations in GBA and LRRK2 Are Not Associated with Increased Inflammatory Markers

Avner Thaler\textsuperscript{a,b,c,d,*}, Nurit Omer\textsuperscript{a,b,d}, Nir Giladi\textsuperscript{a,b,c}, Tanya Gurevich\textsuperscript{a,b,c}, Anat Bar-Shira\textsuperscript{e}, Mali Gana-Weisz\textsuperscript{f}, Orly Goldstein\textsuperscript{f}, Meir Kestenbaum\textsuperscript{b,g}, Julia C. Shirvan\textsuperscript{h}, Jesse M. Cedarbaum\textsuperscript{h,i}, Avi Orr-Urtreger\textsuperscript{b,c,f}, Keren Regev\textsuperscript{b,j}, Shani Shenhar-Tsarfaty\textsuperscript{b,k} and Anat Mirelman\textsuperscript{b,c,d}

\textsuperscript{a}Movement Disorders Unit, Neurological Institute, Tel-Aviv Medical Center, Tel-Aviv, Israel
\textsuperscript{b}Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel
\textsuperscript{c}Sagol School of Neuroscience, Tel-Aviv University, Tel-Aviv, Israel
\textsuperscript{d}Laboratory of Early Markers of Neurodegeneration, Neurological Institute, Tel-Aviv Medical Center, Tel-Aviv, Israel
\textsuperscript{e}Genetic Institute, Tel-Aviv Medical Center, Tel-Aviv, Israel
\textsuperscript{f}Genomic Research Laboratory for Neurodegeneration, Tel-Aviv Medical Center, Tel-Aviv, Israel
\textsuperscript{g}Neurology department, Meir Hospital, Kfar-Saba, Israel
\textsuperscript{h}Biogen Inc, Cambridge, MA, USA
\textsuperscript{i}Coeruleus Clinical Sciences LLC, Woodbridge, CT, USA
\textsuperscript{j}Neuroimmunology Unit, Neurological Institute, Tel-Aviv Medical Center, Tel-Aviv, Israel
\textsuperscript{k}Department of Internal Medicine “C”, “D”, and “E”, Tel-Aviv Medical Center, Tel-Aviv, Israel

Accepted 20 April 2021
Pre-press 11 May 2021

Abstract

Background: Inflammation is an integral part of neurodegeneration including in Parkinson’s disease (PD). Ashkenazi Jews have high rates of genetic PD with divergent phenotypes among GBA-PD and LRRK2-PD. The role of inflammation in the prodromal phase of PD and the association with disease phenotype has yet to be elucidated.

Objective: To assess central and peripheral cytokines among PD patients with mutations in the LRRK2 and GBA genes and among non-manifesting carriers (NMC) of these mutations in order to determine the role of inflammation in genetic PD.

Methods: The following cytokines were assessed from peripheral blood and cerebrospinal fluid (CSF): TNF-\alpha, IL-1\beta, IL-2, IL-4, IL-6, IL-8, IL-10 and INF-\gamma. A comprehensive intake including general medical conditions, use of anti-inflammatory treatments, motor and cognitive assessments and additional laboratory measures were recorded, enabling the construction of the MDS probable prodromal score.

Results: Data from 362 participants was collected: 31 idiopathic PD (iPD), 30 LRRK2-PD, 77 GBA-PD, 3 homozygote GBA-PD, 3 GBA-LRRK2-PD, 67 LRRK2-NMC, 105 GBA-NMC, 14 LRRK2-GBA-NMC, and 32 healthy controls. No between-group differences in peripheral or CSF cytokines were detected. No correlation between disease characteristics or risk for prodromal PD could be associated with any inflammatory measure.

Conclusion: In this study, we could not detect any evidence on dysregulated immune response among GBA and LRRK2 PD patients and non-manifesting mutation carriers.

*Correspondence to: Avner Thaler, MD, PhD, Movement Disorder Unit, Neurological Institute, Tel-Aviv Medical Center, 6 Weizmann Street, Tel-Aviv 64239, Israel. Tel.: +972 3 6973424; Fax: +972 3 6977514; E-mail: avnert@tlvmc.gov.il.

ISSN 1877-7171 © 2021 – The authors. Published by IOS Press. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (CC BY-NC 4.0).
Keywords: Parkinson’s disease, LRRK2, GBA, inflammation

INTRODUCTION

α-synuclein accumulation is the pathological hallmark of Parkinson’s disease (PD). It occurs within the central nervous system (CNS) and in the autonomic nervous system [1]. The neurodegenerative process of PD is associated with an inflammatory response which can be detected in peripheral cytokines, stool samples, and colonic biopsies [2]. Age-dependent spread of α-synuclein from gut to brain has been previously reported [3] raising the possibility that the inflammation and α-synuclein spread are intertwined and represent an early phenomenon in the pathogenesis of PD [4]. However, whether this process is initiated in the CNS or peripheral nervous system (PNS) is still debated [5]. Interestingly, these inflammatory processes occur in patients with a short disease duration [6] and abate with disease progression.

Neuroinflammation in PD is associated with a chronic immune response in the CNS, in which innate immune cells (astrocytes and microglia) are responsible for an inflammatory response and potentially neural death [7]. Whether the microglial response is a consequence of PD related cell death or an independent process is still debated [8]. PD has been associated with the accumulation of pro-inflammatory cytokines including tumor necrosis factor alpha (TNF-α), interferon gamma (INF-γ), and interleukins 6 (IL-6), IL-1β, IL-2, and IL-10 in both cerebrospinal fluid (CSF) and periphery [9, 10]. However, previous studies attempting to correlate motor severity and cognitive profiles of patients with PD and inflammatory markers have yielded conflicting results [9, 11–14].

Among Ashkenazi Jews (AJ), mutations in the LRRK2 and GBA genes together account for about one third of the incidence of the disease [15]. These mutations have been associated with different phenotypes in which GBA confers a more aggressive form of disease compared to a milder form of LRRK2-PD [16]. Decreased activity of the lysosomal enzyme glucocerebrosidase (GCase) results in Gaucher disease (GD) and has been detected in brain tissue and CSF of PD patients [17, 18] with a direct effect on α-synuclein accumulation [19]. Macrophages from GD patients show increased secretion of IL-1β and IL-6 [20] and GBA-PD has been associated with increased levels of IL-8 among other cytokines [21].

LRRK2 is expressed in neurons and in the innate and adaptive immune system [22, 23] with higher levels of immune cells among LRRK2-PD compared to age matched controls [24]. The concentration of peripheral pro-inflammatory cytokines was higher among LRRK2 non-manifesting carriers (NMC) compared to healthy controls [25]. In addition, mutations in the LRRK2 gene have been associated with different inflammatory and infectious diseases such as Crohn’s disease and leprosy [26, 27].

As the penetrance of the mutations in the GBA and LRRK2 genes is incomplete [28], genetic and environmental modifiers are suspected to play a role in disease risk and severity. Identifying modifiers for disease is crucial for better understanding of the mechanism linking both GBA and LRRK2 to PD potentially enabling disease modifying trials.

In this study, we aimed to characterize the inflammatory profile of patients with PD carriers of GBA or LRRK2 mutations and their first-degree unaffected NMC. We hypothesized that the level of inflammatory cytokines among GBA-PD would be greater than that of LRRK2-PD and idiopathic PD (iPD), thus partially explaining the more severe phenotype of GBA-PD. We further hypothesized that increased markers of inflammation will be evident among NMC and that this inflammatory reaction will be correlated with GCase activity and an increase burden of premotor symptoms (higher likelihood ratio for developing PD) among unaffected “at risk” individuals.

METHODS

This study evaluated demographic, laboratory and clinical data from subjects who participated in the BEAT-PD study (TLV-0204–16), a natural history study which set out to characterize LRRK2 and GBA PD as well as NMC of these mutations. For this sub-study, all PD patients and NMC who carried mutations in the GBA gene were recruited together with all LRRK2-NMC, a group of age and disease duration matched iPD and LRRK2-PD, and age matched controls. Patients were recruited if they were AJ, diagnosed with PD by a movement disorders
specialist based on the MDS task force criteria [29] and were at Hoehn and Yahr stages 1-2 [30]. NMC were recruited if they were older than 40 years of age, first degree relatives of GBA-PD or LRRK2-PD, and not diagnosed with PD themselves. All subjects were excluded if they had additional neurological or psychiatric disorders, a malignancy or were HIV, Hepatitis B or C positive. The study was approved by the local ethics committee of the Tel-Aviv Medical Center according to the guidelines of the Helsinki declaration. All participants provided an informed written consent prior to participation.

Procedure

Participants were genotyped for the G2019S-LRRK2 mutation and 9 common mutations in the GBA gene; N370S, R496H, considered mild mutations (mGBA-PD), L444P, 84GG, IVS2 +1G->A, V394L considered severe GBA mutations (sGBA-PD) E326K and T369M, considered risk variants and 370Rec, these mutations account for up to 96% of those found in AJ GD patients [31]. Patients without these mutations were labeled as iPD. Each subject participated in a cross-sectional assessment while 135 subjects agreed to participate in a 5-year longitudinal study, which included CSF collection, MRI and DaT scan three years apart.

Disease severity was assessed using the MDS-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) during ON medication [32]. The Montreal Cognitive Assessment (MoCA) was used to assess global cognitive functions [33]; mood was assessed using the Beck Depression Inventory (BDI) [34]. The Non-Motor Symptoms Questionnaire (NMSQ) [35], the Scale of Autonomic Function in PD (SCOPA-AUT) [36] and the REM sleep Behavior Disorder Questionnaire (RBDQ) were collected [37]. Olfaction was tested using the University of Pennsylvania Smell Identification Test (UPSIT) [38]. These measures were used to calculate the probability for prodromal PD (Likelihood Ratio Score) for all participants without a diagnosis of PD, based on the updated MDS task force prodromal criteria guidelines [39]. Each non-manifesting subject was allocated a ratio between 0–100% for risk for future development of PD based on risk and prodromal symptoms. Levodopa equivalent daily dose (LEDD) was calculated for all patients [40]. In addition, all participants were assessed for inflammatory disease and use of anti-inflammatory medications including aspirin and antibiotics in the days prior to participation.

Blood tests were collected from all participants without an overnight fast. A complete blood count was drawn with white blood count (WBC), hemoglobin, platelet count, absolute lymphocyte and neutrophil levels recorded, and a ratio of lymphocyte/neutrophil (NLR) calculated. Uric acid, urine microalbumin, and CRP were assessed as well.

Blood samples were centrifuged at 1500 × g at 4°C for 15 min, 30 min after blood draw. The serum was separated and aliquoted into 2 ml tubes and placed in a −80°C freezer. For the cytokines panel assay, serum samples were thawed on wet ice and sub aliquoted to 105 µl in cryotubes.

Lumbar punctures were performed in a sub-group of participants as detailed previously [41]. CSF was collected in 15 ml conical tubes and centrifuged at 2000 × g at 25°C for 10 min. The supernatant was collected to a conical tube, aliquoted into 0.5 ml and frozen at −80°C. For the cytokine measurement, the CSF aliquots were thawed on wet ice and sub-aliquoted to 100 µl in cryotubes. The CSF samples were stored in −80°C and shipped in dry ice. CSF and serum were taken at the same day for those who underwent a lumbar puncture.

Human high sensitivity cytokine Luminex custom 8-plex kits were used to assess cytokine levels. The assays were performed in 96-well plates according to the manufacturer’s instructions (R&D Systems, Inc. Minneapolis, MN USA). Standards were run in duplicates, while samples were run in singles. Briefly, the Luminex Assays utilize color-coded superparamagnetic beads coated with analyte-specific antibodies. Beads recognizing different target analytes were mixed together and incubated with the bio-fluid sample. Captured analytes are subsequently detected using a cocktail of biotinylated detection antibodies and a streptavidin-Phycoerythrin conjugate. Magnetic beads were isolated and measured by using the Luminex MAGPIX® Analyzer. The following cytokines were detected in serum and CSF: TNF-α IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, and INF-γ. CSF was assessed for the same cytokines as well.

For the GCase analysis blood samples were collected in a 10 ml EDTA tube. Fifty microliters of whole blood were dropped on each of ten circles on a filter paper and dried at room temperature for at least 4 hours. The filter paper was then stored in a sealed plastic bag at room temperature until the samples were shipped for processing at Centogene (Rostock, Germany). A specific synthetic substrate was added, and the plates were incubated further at 37°C for 16 h. The reaction was stopped by changing
the pH to 10.5. The enzymatic product was quantified by fluorimetry using an external standard curve. The results of the enzymatic activity determination were calculated in $\mu$mol/L/h. As quality parameters for the assays, standard blood samples were added to each batch to ensure the accuracy of the determination.

Statistical analysis

Descriptive statistics (means and standard deviations (SD) for continuous variables) were computed for all measures. Missing cytokine variables were treated with two-imputation methods: 1) Taking the panels’ threshold as the value; 2) Imputed them as 0. The two methods allowed us to examine the sensitivity of the analysis in two extreme ends of possible values.

Log transformation was performed to reduce the natural skewness of the following variables: peripheral cytokines: TNF-α, IL-2, IL-1β, IL-6 and IL-10; CSF cytokines: TNF-α, IL-1β, IL-6 INF-γ. The following laboratory measures were transformed as well: WBC, urine microalbumin, N/L ratio and CRP.

We first created a linear model based on age, disease duration, body-mass index (BMI), use of anti-inflammatory medication and presence of additional inflammatory diseases for each of the CSF/peripheral cytokines. Next, the residuals of each group were compared using Wilcoxon Test in order to avoid any assumption about the residuals’ distribution. Due to the limited number of observations and natural skewness of the measures, we used the non-parametric Wilcoxon’s test which is appropriate when there is no evidence for normal distribution. This test is known to be more powerful than the $T$-test when the number of observations is small and when the normality assumption does not necessarily hold.

$p$-values were adjusted using the Benjamini-Hochberg procedure to control the false discovery rate at level 0.05.

Non-parametric Spearman-rho correlations (used to identify monotonic relationships) between cytokines and additional laboratory and behavioral measures for each study group were assessed. The resulting $p$-values per group were adjusted for multiplicity using the Benjamini-Hochberg method. The threshold of significance was set at 0.05.

Finally, random forest classification was used on the cytokines to classify the participant into genetic groups. This was performed separately for the PD subgroups and the non-manifesting subjects. In this model we used the original cytokine values as explanatory variables in conjunction with the covariates of the linear model detailed above. Since random forest is based on decision trees, it can be used to identify inflammatory profile for each group of participants. Statistical analysis was performed using R version 4.0.3.

RESULTS

Data was collected from 356 participants: 31 idiopathic PD (iPD), 30 LRRK2-PD, 77 GBA-PD, 67 LRRK2-NMC, 105 GBA-NMC, 14 LRRK2-GBA-NMC and 32 healthy controls. Cohort characteristics are presented in Tables 1 and 2.

CSF samples were collected from a subgroup of participants that underwent lumber puncture ($n=80$); 9 iPD, 12 LRRK2-PD, 15 GBA-PD, 10 LRRK2-NMC, 19 GBA-NMC, 5 LRRK-GBA-NMC and 10 controls.

We compared behavioral and laboratory measures within the three groups of PD participants (iPD, LRRK2-PD and GBA-PD) and within the four groups of non-manifesting participants (controls, LRRK2-NMC, GBA-NMC and LRRK2-GBA-NMC).

GCase activity was significantly lower among GBA-PD compared with LRRK2-PD and iPD ($3.02 \pm 0.86$, $5.06 \pm 1.25$ and $4.77 \pm 1.25$, $p<0.001$) and among GBA-NMC and LRRK2-GBA-NMC compared to LRRK2-NMC and controls ($3.08 \pm 0.89$, $3.05 \pm 0.79$, $4.89 \pm 1.31$, $4.86 \pm 1.41$, $p<0.001$), no other behavioral characteristics reached between group significance when correcting for multiplicity (Tables 1 and 2).

Peripheral INF-γ and IL-2 were not included in the analysis as less than 30% of their readings were above threshold. Data regarding missing variables is presented in Supplementary Tables 1 and 2. Data regarding coefficients of variation for each cytokine in serum and CSF is presented as Supplementary Table 3, the inter-plate variability for each cytokine is presented in Supplementary Table 4.

No significant difference in CSF or peripheral cytokine levels were detected between any of the PD subgroups or the non-manifesting subgroups when missing levels were computed as “0” or as the specific batch threshold (Figs. 1 and 2). Furthermore, assessing cytokine differences between mGBA-PD and sGBA-PD and between mGBA-NMC and sGBA-NMC did not yield any differences.

CSF cytokine levels were not correlated with any behavioral or laboratory measures or with risk for prodromal PD among any of the sub-groups.
Table 1
Characteristics of the PD cohort

<table>
<thead>
<tr>
<th></th>
<th>iPD</th>
<th>LRRK2-PD</th>
<th>GBA-PD</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mutation type</td>
<td>N370S – 51</td>
<td>R496H – 5</td>
<td>84GG – 5</td>
<td></td>
</tr>
<tr>
<td></td>
<td>IVS2 – 3</td>
<td>V394L – 3</td>
<td>Rec370 – 2</td>
<td></td>
</tr>
<tr>
<td></td>
<td>L444P – 1</td>
<td>E326K – 5</td>
<td>T369M – 2</td>
<td></td>
</tr>
<tr>
<td>N</td>
<td>31</td>
<td>30</td>
<td>77</td>
<td></td>
</tr>
<tr>
<td>Age (y)</td>
<td>65.77 (10.44)</td>
<td>65.21 (9.99)</td>
<td>64.83 (10.15)</td>
<td>0.906</td>
</tr>
<tr>
<td>Gender M/F (% male)</td>
<td>20/11 (64.5%)</td>
<td>18/12 (60.0%)</td>
<td>54/27 (66.3%)</td>
<td>0.828</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>25.50 (3.22)</td>
<td>25.04 (3.97)</td>
<td>26.25 (4.57)</td>
<td>0.354</td>
</tr>
<tr>
<td>Disease duration (y)</td>
<td>3.69 (1.91)</td>
<td>3.82 (2.66)</td>
<td>3.78 (2.58)</td>
<td>0.980</td>
</tr>
<tr>
<td>Age at diagnosis (y)</td>
<td>62.13 (10.74)</td>
<td>61.70 (9.98)</td>
<td>61.49 (10.03)</td>
<td>0.957</td>
</tr>
<tr>
<td>LEDD</td>
<td>360.98 (296.65)</td>
<td>443.69 (389.38)</td>
<td>456.41 (419.68)</td>
<td>0.506</td>
</tr>
<tr>
<td>MDS-UPDRS</td>
<td>41.87 (15.73)</td>
<td>35.87 (16.94)</td>
<td>40.54 (21.42)</td>
<td>0.430</td>
</tr>
<tr>
<td>MoCA</td>
<td>15.42 (9.85)</td>
<td>20.07 (9.86)</td>
<td>15.43 (9.20)</td>
<td>0.078</td>
</tr>
<tr>
<td>UPSIT</td>
<td>3.13 (3.13)</td>
<td>3.06 (2.29)</td>
<td>3.84 (3.05)</td>
<td>0.377</td>
</tr>
<tr>
<td>SCOPA-AUT</td>
<td>18.34 (9.75)</td>
<td>15.58 (10.87)</td>
<td>15.95 (10.39)</td>
<td>0.613</td>
</tr>
<tr>
<td>GCase (μmol/L/h)</td>
<td>4.77 (1.25)</td>
<td>5.06 (1.25)</td>
<td>3.02 (0.86)</td>
<td>&lt; 0.001*</td>
</tr>
<tr>
<td>WBC (10⁹ / μL)</td>
<td>6.91 (1.52)</td>
<td>7.35 (1.83)</td>
<td>7.13 (1.65)</td>
<td>0.605</td>
</tr>
<tr>
<td>Lymphocytes (10⁹ / μL)</td>
<td>1.75 (0.55)</td>
<td>1.50 (0.45)</td>
<td>1.67 (0.59)</td>
<td>0.219</td>
</tr>
<tr>
<td>Neutrophils (10⁹ / μL)</td>
<td>4.46 (1.21)</td>
<td>5.09 (1.72)</td>
<td>4.71 (1.35)</td>
<td>0.239</td>
</tr>
<tr>
<td>Platelets (10⁹ / μL)</td>
<td>213.00 (53.64)</td>
<td>212.21 (44.42)</td>
<td>209.26 (51.88)</td>
<td>0.926</td>
</tr>
<tr>
<td>C-Reactive Protein (mg/l)</td>
<td>1.44 (1.23)</td>
<td>3.39 (6.30)</td>
<td>1.98 (4.30)</td>
<td>0.204</td>
</tr>
<tr>
<td>Uric Acid (mg/dL)</td>
<td>5.22 (1.24)</td>
<td>5.45 (1.39)</td>
<td>5.41 (1.41)</td>
<td>0.634</td>
</tr>
<tr>
<td>Urine Microalbumin (mg)</td>
<td>6.32 (7.55)</td>
<td>17.26 (58.44)</td>
<td>15.61 (41.42)</td>
<td>0.420</td>
</tr>
<tr>
<td>Presence of any inflammatory disease</td>
<td>7 (22.6%)</td>
<td>4 (13.3%)</td>
<td>10 (12.0%)</td>
<td>0.357</td>
</tr>
<tr>
<td>Use of any anti-inflammatory medication</td>
<td>9 (29.0%)</td>
<td>10 (33.3%)</td>
<td>29 (34.9%)</td>
<td>0.838</td>
</tr>
</tbody>
</table>

Weak, but statistically significant correlations were detected among the total cohort of participants between peripheral cytokine levels and the following measures: CRP and IL-6 ($r = 0.417$, $p < 0.001$), CRP and TNF-α ($r = 0.167$, $p = 0.028$), neutrophil levels and IL-8 ($r = 0.16$, $p = 0.035$), neutrophil levels and IL-6 ($r = 0.188$, $p = 0.017$), uric acid and TNF-α ($r = 0.263$, $p < 0.001$), urine microalbumin and IL-6 ($r = 0.186$, $p = 0.017$), urine microalbumin and TNF-α ($r = 0.178$, $p = 0.021$). IL-6 was correlated with CRP among controls ($r = 0.557$, $p < 0.001$). LRRK2-PD ($r = 0.466$, $p = 0.014$) and iPD ($r = 0.629$, $p = 0.018$). CSF cytokines were not correlated with peripheral cytokines in any of the subgroups of participants.

The probability score for prodromal PD did not correlate with any of the cytokines among all non-manifesting participants or sub-groups assessed separately. GCase activity was not correlated with cytokine levels in any subgroup of participants either.

Performing the same analysis, excluding participants that reported concurrent inflammatory conditions or use of anti-inflammatory medications did not yield any significant findings.

The random forest analysis resulted with high error rates, meaning the explanatory variables alone could not be used to distinguish between the genetic subgroups.

DISCUSSION

In this study assessing a large group of GBA-PD, non-manifesting LRRK2 and GBA mutation carriers, we could not detect a dysregulated immune response based on a panel of both pro and anti-inflammatory cytokines. In addition, disease severity and risk for
Table 2
Characteristics of the Non manifesting participants

<table>
<thead>
<tr>
<th></th>
<th>Controls</th>
<th>LRRK2 NMC</th>
<th>GBA NMC</th>
<th>LRRK2-GBA NMC</th>
<th>Significance</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>32</td>
<td>67</td>
<td>105</td>
<td>14</td>
</tr>
<tr>
<td>Age (y)</td>
<td>54.82(10.03)</td>
<td>54.45(12.46)</td>
<td>54.88(10.03)</td>
<td>52.00(11.48)</td>
<td>0.803</td>
</tr>
<tr>
<td>Gender M/F (%) male</td>
<td>13/20</td>
<td>33/34</td>
<td>38/68</td>
<td>5/9</td>
<td>0.368</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>26.16 (4.05)</td>
<td>26.14 (4.23)</td>
<td>26.70 (4.73)</td>
<td>25.77 (3.94)</td>
<td>0.771</td>
</tr>
<tr>
<td>Probability of prodromal (%)</td>
<td>9.81 (24.60)</td>
<td>20.84 (31.52)</td>
<td>29.10 (33.45)</td>
<td>14.40 (23.72)</td>
<td>0.014*</td>
</tr>
<tr>
<td>Probability above 80% n (%)</td>
<td>0</td>
<td>8 (11.94)</td>
<td>18 (17.15)</td>
<td>1 (7.14)</td>
<td>0.058</td>
</tr>
<tr>
<td>MDS-UPDRS</td>
<td>4.85 (4.76)</td>
<td>5.33 (4.29)</td>
<td>5.94 (6.85)</td>
<td>7.69 (9.25)</td>
<td>0.437</td>
</tr>
<tr>
<td>MoCA</td>
<td>31.30 (6.97)</td>
<td>31.23 (5.07)</td>
<td>29.88 (6.52)</td>
<td>32.36 (3.91)</td>
<td>0.142</td>
</tr>
<tr>
<td>UPSIT</td>
<td>7.66 (5.74)</td>
<td>8.58 (7.05)</td>
<td>8.29 (7.43)</td>
<td>9.80 (7.41)</td>
<td>0.344</td>
</tr>
<tr>
<td>RBDQ</td>
<td>1.79 (1.45)</td>
<td>1.40 (1.46)</td>
<td>1.95 (1.91)</td>
<td>1.76 (1.09)</td>
<td>0.122</td>
</tr>
<tr>
<td>SCOPA-AUT</td>
<td>4.86 (1.41)</td>
<td>4.89 (1.31)</td>
<td>3.08 (0.89)</td>
<td>3.05 (0.79)</td>
<td>&lt;0.001^</td>
</tr>
<tr>
<td>WBC (10³/µL)</td>
<td>7.52 (2.18)</td>
<td>6.60 (1.50)</td>
<td>6.94 (2.01)</td>
<td>6.18 (1.16)</td>
<td>0.056</td>
</tr>
<tr>
<td>Lymphocytes (10³/µL)</td>
<td>2.09 (1.25)</td>
<td>1.81 (0.48)</td>
<td>1.91 (0.56)</td>
<td>1.90 (0.55)</td>
<td>0.299</td>
</tr>
<tr>
<td>Neutrophils (10³/µL)</td>
<td>4.72 (1.76)</td>
<td>4.11 (1.19)</td>
<td>4.35 (1.8)</td>
<td>3.59 (0.77)</td>
<td>0.097</td>
</tr>
<tr>
<td>Platelets (10³/µL)</td>
<td>228.09 (56.14)</td>
<td>226.09 (54.16)</td>
<td>229.60 (55.95)</td>
<td>222.80 (37.25)</td>
<td>0.961</td>
</tr>
<tr>
<td>C-Reactive Protein (mg/l)</td>
<td>2.56 (5.67)</td>
<td>1.78 (2.03)</td>
<td>2.71 (4.21)</td>
<td>1.87 (2.07)</td>
<td>0.449</td>
</tr>
<tr>
<td>Uric Acid (mg/dL)</td>
<td>4.79 (1.16)</td>
<td>5.24 (1.42)</td>
<td>5.07 (1.41)</td>
<td>5.26 (1.66)</td>
<td>0.446</td>
</tr>
<tr>
<td>Urine Microalbumin (mg)</td>
<td>8.93 (20.45)</td>
<td>18.45 (55.95)</td>
<td>5.62 (15.22)</td>
<td>5.50 (9.82)</td>
<td>0.384</td>
</tr>
<tr>
<td>Presence of any Inflammatory disease</td>
<td>7 (21.2%)</td>
<td>7 (10.4%)</td>
<td>19 (17.9%)</td>
<td>4 (25.0%)</td>
<td>0.351</td>
</tr>
<tr>
<td>Use of any Anti-inflammatory medication</td>
<td>8 (24.2%)</td>
<td>14 (20.9%)</td>
<td>24 (22.6%)</td>
<td>12 (15.9%)</td>
<td>0.800</td>
</tr>
</tbody>
</table>

NMC, non-manifesting carrier; M, male; F, female; BMI, body mass index; MDS-UPDRS, Movement Disorder Society - Unified Parkinson’s Disease Rating Scale; MoCA, Montreal Cognitive Assessment; UPSIT, University of Pennsylvania Smell Identification Test.; GCase, beta glucocerebrosidase; WBC, white blood cells. Data is shown as mean ± standard deviation or percentage. *Significant difference between GBA-NMC, LRRK2-NMC and NMNC, LRRK2-GBA-NMC. ∧Significant difference between GBA-NMC, LRRK2-GBA-NMC and LRRK2-NMC, NMNC.

probability of prodromal PD were not associated with specific cytokine levels or combination of cytokines.

In the central nervous system, resident immune system is comprised mostly of innate immune cells, with microglia and astrocytes as the main components. Under certain conditions, peripheral innate and adaptive immune cell can enter the CNS [42]. This reaction can be beneficial or deleterious depending on its severity and duration. Although cytokines participate in the inflammatory process, most have multiple biological targets and activities. The specific role of any cytokine in a clinical setup is dependent on the spectrum of polypeptides that are secreted alongside it.

With accumulating evidence that GI symptoms are present from the earliest stages of PD, it has been proposed that PD pathology may originate in the gut and later spread to the CNS. Immune activity may advance this progression, as intestinal inflammation can promote systemic and also CNS inflammation [43] contributing to PD-related neurodegeneration [44]. Immune activation promotes increased α-synuclein expression and aggregation [45] and α-synuclein in turn stimulates proinflammatory immune responses [46], resulting in a positive feedback loop.

However, data regarding cytokine expression in PD is conflicting: The ICICLE study assessed early PD patients and detected elevation of TNF-α, IL-1β, IL-2 and IL-10 compared with controls [13]. While elevated levels of cytokines including IL-1β, IL-2, TNF-α, IL-6 IL-10 and CRP have been reported among patients with PD compared with controls in a comprehensive meta-analysis [10]. However, the pooling of different studies, included patients in different disease stages, disease duration, use of medication and concomitant medical condition, is a limitation of this meta-analysis.
As CSF is in close contact with the CNS, paired plasma and CSF assessments may provide insight into the relationship between peripheral and central inflammation in PD. However, our study, in line with previous reports, failed to detect any correlation between cytokines analyzed in the CSF and serum of PD patients and NMC [47]. A recent post-mortem study examined mRNA levels of cytokines and mediators of the immune response from PD patients across different disease stages and found increased expression of IL-6 in the substantia nigra of patients in early disease stage while at later stages of the disease the same marker was downregulated [48]. In this work however, we could not detect evidence of central or peripheral inflammation, at least as reflected in ambient cytokine concentrations, among patients with PD or NMC of disease related mutations when correcting for anti-inflammatory medications or additional inflammatory conditions or when excluding participants with these conditions. We did detect correlations between pro-inflammatory cytokines and pro-inflammatory laboratory measures such as CRP, uric acid and microalbumin [49, 50] indicating that states that are associated with increased inflammation were associated with increased pro-inflammatory cytokines.

The pathological hallmark of GD is the accumulation of characteristic macrophages containing glycolipids (Gaucher cells) leading to chronic inflammation [51]. Glycolipid accumulation and lysosomal dysfunction in GD prime macrophages to release pro-inflammatory cytokines [52, 53] and indeed, in GD cell lines, activated microglia and astrocytes were detected prior to cell loss with an increase in pro-inflammatory cytokines [54]. Patients with type 1 GD showed elevated serum IL-6 [53]. Homozygote PD GBA carriers were found to have elevated plasma levels of ferritin, CCL18 and MIP1α but heterozygotes PD and NMC did not differ from controls in their inflammatory profile [55]. While a small study with
17 GBA-PD detected increased levels of IL-8 among other cytokines [21]. We could not detect any differences in cytokine profiles between GBA-PD and iPD or between GBA-NMC and NMNC even when separating the GBA cohort based on type of mutation (mild, variant, or severe), within a large cohort of participants.

Data regarding inflammation among LRRK2-PD and LRRK2-NMC is conflicting. While platelet-derived growth factor (PDGF) was higher among LRRK2-PD compared to iPD [56], other studies detected an increase in both pro-inflammatory markers (IL-12-p40) and anti-inflammatory markers (IL-10 and brain-derived neurotrophic factor (BDNF)) among iPD compared with LRRK2-PD [57]. Among LRRK2-NMC, peripheral IL-1β was significantly higher compared with controls when corrections for age, sex, current and past use of anti-inflammatory medications [25], CSF TNF-α was reported to be higher in LRRK2-NMC than in controls [58]. However, these findings were not replicated in other studies [57] or herein, possibly due to the lower age and number of controls in our study, use of concomitant inflammatory conditions as a covariate, and use of more stringent corrections for multiplicity in our study.

The penetrance of the mutations in the GBA and LRRK2 genes is incomplete [28], thus including all non-manifesting mutation carriers together as one group has the potential of combining participants that will and will not convert to PD within different timeframes. An MDS task force has suggested and updated criteria for detection of the prodromal stages of the disease [39]. Potentially, it is only those participants that are at the prodromal stage of the disease that might have an elevated inflammatory response. Comparing the 27 NMC with a probability score of above 80 to those with a lower score, did not yield any significant difference in cytokine levels. However, this might be related to the low number of NMC with high probability scores.
While this is the largest study to date to assess inflammatory measures in GBA related PD and NMC, several limitations need to be addressed. First, the cross-sectional set-up is problematic when assessing the inflammatory profile of this cohort as daily changes in cytokine levels are well recognized. We used a targeted approach for the assessment of mutations in the LRRK2 and GBA genes and did not perform a complete sequencing of these genes as the 9 mutations in the GBA gene assessed herein account for over 96% of the known AJ mutations in GD [31] and the vast majority of LRRK2 mutations, notwithstanding, this method might have missed rare mutation carriers and thus labeled them as iPD. The sub-group of participants who underwent lumbar puncture and CSF assessment and longitudinal analysis was relatively small. While the choice of pro and anti-inflammatory cytokone was based on previous disease related studies, the use of high sensitivity kits with no related analysis of immune cells remains a limitation especially when some of the cytokines were below detection levels among the majority of participants. We thawed our blood and CSF samples for sub-aliquotation of 100 μl before cytokine analysis. While all samples were aliquoted on dry ice and using the same protocol, this extra thaw-freeze cycle could affect cytokines stability differently. However, this would have a similar effect on all groups.

The role of inflammation in neurodegeneration and PD specifically seems robust with epidemiological evidence of reduced risk for PD among Inflammatory bowel disease patients treated with anti-TNF medication [59], indicating a role for monocyte activation factors and disease progression [60]. There still exists an unmet need for establishing a reliable approach for the study of neuroinflammation in PD patients and prodromal subjects. A combination of blood and CSF cytokines, cellular immunity and brain imaging might help to elucidate the relationship between inflammation, neurodegeneration and α-synuclein, but is extremely difficult to execute.

In this comprehensive analysis of central and peripheral inflammatory measures among LRRK2 and GBA PD and NMC, we could not detect any pro-inflammatory signal related to disease risk or phenotype. Future studies assessing other components of the immune system are warranted to establish the role of inflammation in the prodromal period and after disease diagnosis to determine whether the immune system might be targeted with interventions aimed to modify PD.

ACKNOWLEDGMENTS

This work was funded by the MJFF grant #16503, the Silverstein Foundation for Parkinson’s with GBA and by Biogen Inc.

CONFLICT OF INTEREST

AT – Receiving honoraria from Abbvie Israel.

NO – Nothing to disclose

NG – Serves on the Editorial Board of the Journal of Parkinson’s Disease. Serves as consultant to Biogen, Genzyme-Sanofi, Sionara, NeuroDerm, Intec Pharma, Pharma2B, Denali Neuron23 and Abbvie. Receives royalties from Lysosomal Therapeutics (LTI) and payment for lectures from Abbvie, Sanofi-Genzyme, Bial and Movement Disorder Society.

Received research support from the Michael J Fox Foundation, the National Parkinson Foundation, the European Union 7th Framework Program, the Israel Science Foundation, Teva NNE program, Biogen, LTI, and Ionis.

TG – Advisory board membership with honoraria from Abbvie, Neuroderm, Medison, Allergan, Cytora and Synmerva, research support from Phoentic Ltd., Israeli Innovation Authority, Sagol School of Neuroscience and Parkinson’s Foundation. Receiving travel support from Abbvie, Allergan, Medison and Medtronic.

ABS – Nothing to disclose

MGW – Nothing to disclose

OG – Nothing to disclose

MK – Payment for lectures from Abbvie and Teva.

JCS – Employee and shareholder in Biogen, Inc.

JMC – A former employee and shareholder in Biogen, Inc.

AOU – Research support from the Michael J Fox Foundation, Chaya Charitable Fund and Biogen and payment for lectures from Sanofi Genzyme and Pfizer.

KR – Lecture fees and travel grants from Teva, BMS, Biogen, Sanofi Genzyme, Roche, Medison, Novartis and Serono.

SST – Nothing to disclose

AM – Serving as advisor to Neuroderm.

SUPPLEMENTARY MATERIAL

The supplementary material is available in the electronic version of this article: https://dx.doi.org/10.3233/JPD-212624.


profile in LRRK2-associated prodromal and clinical PD. 

*J Neuroinflammation* **13**, 122.

